Hiroo Ishida

Showa University Fujigaoka Hospital — Japan

Medicine · Health Sciences

23h-index1.2kcitations157works0.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(76), Colorectal Cancer Treatments and Studies(32), Quinazolinone synthesis and applications(28), Cancer therapeutics and mechanisms(25), Lung Cancer Research Studies(21)

Publications157 total

Polymorphisms of FGFR Pathway-related Factors and Capecitabine-induced Hand-foot Syndrome in Japanese Patients With Colorectal Cancer
Anticancer Research·2026Open Access
Association of IL12RB2, RORC, and class II HLA polymorphisms with severe erythema multiforme of regorafenib in Japanese patients with colorectal cancer
Cancer Chemotherapy and Pharmacology·2025
Long-Term Outcomes of Cross-Match Positive Living Kidney Transplantation: A Retrospective Study
American Journal of Transplantation·2025Open Access
<i>ABCC4</i> polymorphism indirectly reduces systemic exposure to a capecitabine metabolite 5′‐deoxy‐5‐fluorouridine in Japanese subjects
British Journal of Clinical Pharmacology·2025· 1 citedOpen Access
Post-recurrence survival in patients with stage III gastric cancer who received adjuvant chemotherapy; post-hoc analysis of the JACCRO GC-07 study
European Journal of Cancer·2025
Cost-effectiveness analysis of first line pembrolizumab monotherapy for high programmed cell death ligand 1 expressed, advanced non-small cell lung cancer in Japan
International Journal of Clinical Pharmacy·2024Open Access
Association Between<i>ABCC2</i>−24C&gt;T and Nab-Paclitaxel-induced Peripheral Neuropathy in Japanese Patients With Pancreatic Cancer
Anticancer Research·2024· 1 citedOpen Access
Abstract CT032: Promotive clinical effects of pembrolizumab with necitumumab in patients having advanced non-small cell lung cancer with PD-L1 expression of 50% or higher in a phase II study (K-TAIL-202)
Cancer Research·2024· 1 cited
Association of VEGFA and CCL4L2 polymorphisms with hand-foot skin reaction and survival of regorafenib in Japanese patients with colorectal cancer
Cancer Chemotherapy and Pharmacology·2024· 2 cited
MO3-3 Phase II study of S-1+CDDP with concurrent TRT followed by durvalumab for unresectable LA-NSCLC in Japan (SAMURAI)
Annals of Oncology·2023Open Access
A polymorphism in ABCA2 is associated with neutropenia induced by capecitabine in Japanese patients with colorectal cancer
Cancer Chemotherapy and Pharmacology·2023· 2 cited
Associations of <i>HLA‐C*01:02</i> and <i>HLA‐B*46:01</i> with regorafenib‐induced erythema multiforme in Japanese patients with metastatic colorectal cancer
Clinical and Translational Science·2023· 6 citedOpen Access
Supplementary Figure 4 from Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation
2023Open Access
Supplementary Figure Legends from Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation
2023Open Access
Figure S3 from Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI–Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation
2023Open Access
Supplementary Figure 5 from Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation
2023Open Access
Supplementary Figure 2 from Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation
2023Open Access
Table S1 from Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI–Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation
2023Open Access
Table S2 from Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI–Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation
2023Open Access
Data from Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI–Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation
2023Open Access
page 1 of 8Next →

Frequent Co-authors

Ken‐ichi Fujita(23), Yasutsuna Sasaki(22), Takashi Hirose(16), Yutaro Kubota(13), Tohru Ohmori(12), Sojiro Kusumoto(11), Yu Sunakawa(11), Takao Shirai(10), Tsukasa Ohnishi(10), Keishi Yamashita(9), Takuya Tsunoda(9), Toshimitsu Yamaoka(8), Kaori Kawara(8), Mitsuru Adachi(8), Tomohide Sugiyama(7), Kentaro Okuda(7), Fumio Nagashima(7), Wataru Ichikawa(7), Naoya Horichi(7), Keisuke Miwa(7)